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Background: Microwave ablation (MWA) has attracted a worldwide attention gradually in treating inoperable
pulmonary malignancies. However, in the lung tissues treated with MWA recurrence of tumor may still occur and
few data in large patient groups till now were reported about the safety or effectiveness of microwave ablation in
treating primary lung cancer and metastatic pulmonary malignancies. The purpose of this study is to evaluate the
clinical curative effect (local control, survival data) MWA and its safety as well.
Methods: From 1 January 2005 to 1 January 2008, retrospective analyses, 69 patients underwent computed
tomography (CT)-guided percutaneous MWA of pulmonary malignancies. All patients were deemed medically
inoperable. The correlation of tumor sizes and local progression after ablation was analyzed and the survival rates
within 3 years post surgery were compared between non-small-cell lung cancer and pulmonary metastases groups
also.
Results: Pneumothorax was the most frequent complication and occurred in 24.64% patients after ablation. Neither
needle track implantation was found nor did patient death occur in these patients within 30 days. The 1-, 2-, and
3-year overall survival rates were 66.7%, 44.9% and 24.6%, respectively. The overall survival rates for NSCLC patients
in 1 year, 2 years, and 3 years were 75.0%, 54.2%, and 29.2%, respectively. The overall survival rates for pulmonary
metastatic tumor patients in 1 year, 2 years, and 3 years were 47.6%, 23.8%, and 14.3%, respectively. The recurrence-
free survival rates for NSCLC patients in 1 year, 2 years, and 3 years were 72.9%, 50.0%, and 27.1%, respectively. The
mortality rates for pulmonary metastatic tumor patients in 1 year, 2 years, and 3 years were 47.6%, 19.0%, and
14.3%, respectively.
Conclusions: Percutaneous microwave coagulation therapy was one safe and effective method and could be
beneficial for the improvement of inoperable pulmonary malignancies treatment effect.
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Surgical operation is the preferred standard treatment
for primary lung cancer patients [1,2]. However many
patients were poor surgical candidates owing to insuffi-
cient cardiopulmonary function, old age, or other medical
co-morbidities as well as those with pulmonary metastasis
tumors, a life-threatening event with bad survival rates [3].
In recent years, tumor heating ablation such as radiofre-
quency ablation under the guidance of image has been* Correspondence: han-yong@live.cn; lxfchest@126.com
†Equal contributors
1Department of Thoracic Surgery, Tangdu Hospital, The Fourth Military
Medical University, Xi’an, People’s Republic China
Full list of author information is available at the end of the article
© 2012 Lu et al.; licensee BioMed Central Ltd.
Commons Attribution License (http://creativec
reproduction in any medium, provided the orproved to be an alternative treatment method for these
patients with definite effects [4-8], and as a new minimally
invasive technique, percutaneous microwave coagulation
therapy (PMCT) has attracted a worldwide attention
gradually in treating inoperable pulmonary malignancies.
Electromagnetic waves were used in microwave ablation
(MWA) to produce tissue heating effects and would result
in a much larger zone of active heating when compared
with that of radiofrequency ablation, which made PMCT a
more precise and more reliable method in treating malig-
nancies in many tissues [9-11]. However few data in large
patients groups till now were reported about the safety or
effectiveness of MWA in treating primary lung cancer and
metastatic pulmonary malignancies. The purpose of thisThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and its safety as well.Methods
Study design and setting
This retrospective study was conducted in a single institu-
tion. Malignancies in all patients which included primary
or recurrent non-small-cell lung cancer (NSCLC) and
metastatic pulmonary malignancies were deemed medically
inoperable. All patients underwent computed tomography
(CT)-guided PMCT of pulmonary malignancies. The first
PMCT procedures started in 2005. The endpoints were
local efficacy, complications, and overall and disease-free
survival.
From 1 January 2005 to 1 January 2008, retrospective
analyses, 69 patients (45 males and 24 females; mean age
65 years ± 15 years (standard deviation)) underwent per-
cutaneous MWA. Ninety-three intrapulmonary nodules
were treated with PMCT (there were 106 intrapulmonary
nodules detected by the CT, with 1.54 nodules for one
patient on the average). With the agreement of Hospital
Ethics Committee, all patients signed written informed
consent before the treatment.
Inclusion criteria for patients receiving MWA of pul-
monary malignancies were as follows: (1) age: 18–80 years;
(2) having lost the opportunity of surgical resection or
cannot endure surgical treatment because of other diseases
(severe dysfunctions of heart, lung, liver, kidney, and so
on); (3) with stage IIIB (according to UICC international
NSCLC staging criteria) NSCLC or pulmonary metastasis
tumor, and definite pathological diagnosis; or (4) patient
refusing to undergo surgery.
Exclusion criteria were as follows: (1) patients with ser-
ious failure of the function of important organs (heart, liver,
lung, and kidney); (2) patients with hilum pulmonis lesions
and companied by larger cavity; (3) patients with central-
type pulmonary malignancies and companied by severe
obstructive pneumonia, patients with cancer involving
main bronchus; (4) patients with pulmonary malignancies
transferred to neck and thoracic vertebra, causing severe
destruction of vertebral body and risk of paraplegia; or (5)
patients with pulmonary diffuse metastatic lesions.Image-guided microwave thermal ablation
Ablation in all patients was performed with CT fluoroscopic
guidance, with 5-mm collimation and 10–50 mA, to
localize the tumor. Interventional radiologists performed
lung MWA under the guidance of CT scan. Standard sur-
gical prepping and draping was performed. Local
anesthesia included 2% lidocaine both intradermally and
deeper to the pleural surface. Patients were under con-
scious sedation using 0.5-1.0 mg doses of midazolam and
25–50 μg doses of fentanyl. Patients were monitored withcontinuous pulse oximetry and ECG. Blood pressure was
measured every 5 min.
Percutaneous entry route was determined on the basis
of tumor size, morphology, location, adjacent structures,
and access route. Tumors that were <2 cm in maximal
diameter were treated with a single applicator which was
placed in the center of the tumor. To make the ablation
range completely cover the tumors and 1 cm around
them, tumors that were 2 cm or larger were treated with
two to three different sites based on tumor size and
shape. After the treatment, CT scan was performed again
to define the change conditions of tumor and images of
1 cm range around it.
The microwave generator (Viva-Wave Microwave Coagu-
lation System; Valley Lab) was capable of producing up to
60 W of power at a frequency of 915 MHz. A peristaltic
pump perfused the outer shaft of the antenna with room-
temperature normal saline at a rate of 60 mL/min to pre-
vent thermal injury along the proximal antenna shaft. Abla-
tion times were recorded for all procedures. Procedure
success was determined by measuring an intratumoral
temperature greater than 60°C or a sustained temperature
of 55°C over more than one measurement. The total abla-
tion time were adhered to in all cases, on the condition that
the patients were able to tolerate.
Patients were observed for a minimum of 3 h after the
procedure, with chest radiography performed at 2 h to
assess for pneumothorax. Penicillin was administered
prophylactically 3 days after MWA.
Complications and follow-up
Treatment-related complications being counted were
only within 30 days after ablation, and were classified in
accordance with the Common Terminology Criteria for
Adverse Events version 4.0 (CTCAE) [12]. Minor com-
plications were defined as those resulting in no sequelae
or needing nominal treatment or a short hospital stay for
observation, which were Grade 1 or 2 adverse events.
Major complications were defined as those resulting in
readmission to the hospital for treatment, an unplanned
increase in the level of care, extended hospitalization,
permanent adverse sequelae, which were Grade 3 or 4
adverse events. Any patient death within 30 days of
image-guided tumor ablation (grade 5 adverse events)
was addressed.
Routine CT scan was performed after 1 month, then
every 3 months for 3 years. Contiguously reconstructed
sections (1:1 pitch) were obtained through the thorax in
a single breath-hold, with 5-mm collimation. Median
follow-up was 18 months. All CT scans during follow-
up were done on the same CT unit and evaluated by
the same group of radiologists. A modified Response
Evaluation Criteria in Solid Tumors (RECIST) criterion
incorporating CT scan was utilized to evaluate initial
Table 1 Patient characteristics (NSCLC, n=48)
Variable Result
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defined as any increase in the size of the measurements
found on follow-up CT examinations. Stability or any
decrease in size was considered as no local progression.
Based on RECIST, quantitative analysis for local develop-
ment of tumor was divided into: complete response (CR),
partial response (PR), stable disease (SD), and progressive
disease (PD) [13-15].NSCLC, n (%)
Stagea I 7 (14.58)
Stagea II 10 (20.83)
Stagea III 22 (45.84)
Stagea IV 9 (18.75)
Previous therapy, n (%)
No surgerya 26 (54.17)
Lung resection (recurrent) 22 (45.83)
Reasons for no surgery, n (%)
Poor lung function 22 (45.83)Statistical analysis
Comparison of continuous data was performed by t test.
Statistical analysis was performed by Chi-square test.
Overall survival was calculated as the time between and
the date of death or last news of the patient with the
Kaplan-Meier technique and SPSS software, version 16.0
(SPSS, Chicago, IL, USA). Median follow-up time was
calculated by the inversed Kaplan-Meier technique. Statis-
tical significance was set at a P level of< 0.05.Sever cardiac risk 11 (22.92)
Poor performance status 8 (16.67)
Multiple co-morbidities 7 (14.58)
Length of hospital stay (days)
Mean (range) 4.5 (3–27)
aPatients included without therapy, chemotherapy. or radiotherapy.
NSCLC, non-small-cell carcinoma.Results
MWA
There were 26 patients of primary non-small-cell car-
cinoma pulmonary malignancies, 21 patients of metastatic
pulmonary malignancies, and 22 patients of recurrent pul-
monary malignancies in total. There were 47 patients with
the diameter of 72 tumor nodules which were treated with
PMCT less than 3 cm, 12 patients with the diameter of 12
tumor nodules more than 4 cm, and the diameter of the
rest 19 tumor nodules was 3–4 cm, 12 patients in total.
The average diameter of tumor nodules was about
22.3± 1.7 mm (8–55 mm). All patients received 3 years
postoperative follow-up. For patient characteristics, see
Table 1 (NSCLC) and Table 2 (pulmonary metastasis
tumor).Complications
No needle track implantation and no patient deaths were
found within 30 days after the operation. There were 17
out of 69 (24.64%) patients with complications following
this procedure. Pneumothorax was the most frequent
complication and occurred in 13 (18.84%) patients, in-
cluding mild pneumothorax with no requirement for
treatment (n= 8, 11.59%), thoracentesis (n= 4, 5.80%),
and one (1.45%) severe pneumothorax received thoracic
cavity closed drainage. Of these 13 patients who suffered
pneumothorax, 10 patients had emphysema before abla-
tion and two patients were accompanied by a small
number of bullae. Other complications included five
(7.25%) hemoptysis, two (2.90%) hemothorax, three
(4.35%) pneumonitis, two (2.90%) chest pain without
treatment, and two (2.90%) fever with temperature lower
than 38.5°C (Table 3).Tumor progression
Fifteen patients (21.74%) appeared with in situ local pro-
gress of masses. Among the 69 patients treated by MWA,
the diameters of 47 patients were <3 cm, that of 12 patients
were 3–4 cm, and that of the remaining 10 were >4 cm.
During the MWA treatment for 91 pulmonary malignancies
nodules, 178 different parts received MWA treatment in
total. There were 2±1 parts ablated for every tumor on the
average.
Local progression rate of tumor within 3 years reached
16.13% (n= 15). There was no significant difference for
local progression between tumors with diameters <3 cm
and 3–4 cm (P= 0.373), but there was statistic difference
between them and tumors with diameters >4 cm
(P= 0.0396, P= 0.029, respectively) (Table 4).Survival
The Kaplan-Meier median progress-free period for all
patients (n=69) was 22.0 months (95% confidence interval
(CI) 15.023–28.977 months). The overall survival rates in
1 year, 2 years, and 3 years are 66.7%, 44.9%, and 24.6%,
respectively; the overall survival rates for NSCLC patients
in 1 year, 2 years, and 3 years were 75.0%, 54.2%, and
29.2%, respectively; and the overall survival rates for
pulmonary metastatic tumor patients in 1 year, 2 years,
and 3 years were 47.6%, 23.8%, and 14.3%, respectively
(Figure 1). The median death period for all patients
Table 2 Patient characteristics (pulmonary metastasis
tumor, n= 21)
Variable Result





Primary tumor, n (%)
Breast cancer 3 (14.28)
Prostate cancer 4 (19.05)
Liver cancer 7 (33.33)
Gastrointestinal cancer 7 (33.33)
Previous therapy, n (%)
No surgerya 11 (52.38)
Surgery 10 (47.62)
Reasons for no surgery, n (%)
Poor lung function 12 (57.14)
Sever cardiac risk 5 (23.81)
Poor performance status 2 (9.52)
Multiple co-morbidities 2 (9.52)
Length of hospital stay (days)
Mean (range) 4.8 (3–32)
aPatients included without therapy, chemotherapy, or radiotherapy.







(CR, PR, SD), n (%)
Local progression
(PD), n (%)
<3 cm 47 38 (87.33) 9 (12.67)
3-4 cm 12 11 (91.67) 1 (8.33)
>4 cm 10 5 (50.00) 5 (50.00)
<3 cm vs. 3–4 cm, x2 = 0.794, P= 0.373;< 3 cm vs. >4 cm, x2 = 4.236, P=0.0396;
3–4 cm vs. >4 cm, x2 = 4.774, P= 0.029; CR, complete response; PD, progressive
disease; PR, partial response; SD, stable disease.
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http://www.wjso.com/content/10/1/80recurrence-free was 24.0 months (95% CI 17.828–
30.172 months). The recurrence-free survival rates for
NSCLC patients in 1 year, 2 years, and 3 years are 72.9%,
50.0%, and 27.1%, respectively; and the mortality rates
for pulmonary metastatic tumor patients in 1 year,
2 years, and 3 years are 47.6%, 19.0%, and 14.3%, re-
spectively (Figure 2). There were no significant differ-
ences in either the overall survival rates or the
recurrence-free survival rates for NSCLC and pulmon-











Acute respiratory distress syndrome 0
aThe rate was calculated by dividing the number of ablation sessions in
parentheses by the total number of ablation sessions (n= 69).
bChest tube required.Discussion
The preferred therapeutic schedule for pulmonary malig-
nancies is surgical treatment, but for those inoperable
pulmonary malignancies patients who cannot endure
surgical treatment because of various reasons (such as
advanced pulmonary malignancies, recurrent pulmonary
malignancies, metastatic pulmonary malignancies, and so
on), various comprehensive treatment methods had to be
carried out to improve the long-term survival rates of
such patients [16-18]. Tumor heating ablation under the
guidance of image has been proved to be one treatment
method with definite effects [19,20], and the method of
treating inoperable pulmonary malignancies with percu-
taneous microwave coagulation therapy (PMCT) is one
of the new minimally invasive technique popular in
recent years [21,22].
MWA uses electromagnetic waves to produce tissue
heating effects and would result in a much larger zone of
active heating when compared with that of radiofre-
quency ablation for its greater convection profile in lung
and less severe heat sink effects. Furukawa et al. also
found that tissues around the electrodes changed imme-
diately after MWA, that is fibrosis and thickening of col-
lagenous fibre [23]. The ablated pulmonary tissues would
be replaced by scar fibrous tissues after 6 months.
The clinical safety of MWA has been proved in some
clinical studies. Wolf [24] reported that there was no
patient death within 30 days after the operation, and the
first death appeared 256 days after MWA because of a fatal
massive hemoptysis. He et al. [25] treated 16 tumors in 12
patients with MWA therapy under the guidance of ultra-
sound, and follow-up was carried out for 20 months on the
average. In this group, seven patients survived with no se-
vere complications, and five patients died of metastasis.
Nevertheless more data, especially in large patient group,
were still needed for evaluating the safety and effectiveness
of MWA in treating primary pulmonary malignancies and
metastatic pulmonary malignancies.
In our group, all patients survived within 30 days, and
complications occurred in 17 patients (24.64%). The most
common complication after percutaneous PMCT treatment
was pneumothorax caused by pulmonary needle biopsy,
and the incidence rate of pneumothorax was about 15% to
Figure 1 Kaplan–Meier curve of overall survival rates for NSCLC and pulmonary metastasis tumor group treated with MWA. (P=0.024).
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pneumothorax was 18.84%. Of these, 13 patients suffered
pneumothorax, 10 patients had emphysema before ablation,Figure 2 Kaplan–Meier curve of recurrence free survival rates for NSC
(P=0.015).and two patients were accompanied by a small number of
bullae, so it was suggested that emphysema and bullae may
be the risk factors of pneumothorax in PMCT treatment.LC and pulmonary metastasis tumor group treated with MWA.
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pneumothorax, no treatment was needed and the incidence
rate of thoracic cavity puncture and closed drainage was
5.80% and 1.45%, respectively. Other common complica-
tions after PMCT operation include blood-stained sputum,
hemothorax and pulmonitis, and so on. The incidence rate
of chest pain within 1–2 h after microwave ablation was
2.90%, all of which were patients with tumors close to the
thoracic wall.
The first patient died of massive hemoptysis 207 days
after the MWA therapy in our group. The pulmonary
malignancies in this patient were located in the periphery
of the pulmonary artery, with a diameter of 4 cm, and
the patient received 3x MWA on different parts during
the operation. A larger cavity was found in the CT scan
3 month after the operation, which may be the primary
cause of massive hemoptysis. It was found that the
tumor position in almost all patients that appeared as
blood-stained sputum after operation was adjacent to
bronchia, pulmonary artery, and pulmonary vein, which
suggested that it was a risk factor for massive hemoptysis
when the tumor was located near the bronchia, pulmonary
artery, and pulmonary vein. Therefore appropriate criteria
should be set for patients receiving PMCT treatment, and
a well-trained and experienced clinician was needed to
reduce the complications when performing PMCT.
The clinical efficacy of microwave ablating was the
most valuable fact in treating inoperable pulmonary ma-
lignancies. In early reports, the local progress rates of
pulmonary malignancies after PMCT were confused
[24,28,29]. The median progress-free period, survival rate
in 1 and 2 years and tumor’s local progress in our study
suggested that MWA therapy was definitely effective, es-
pecially for patients with non-metastatic pulmonary ma-
lignancies. For patients with metastatic pulmonary
malignancies, the result was unsatisfied, which might be
owing to later cancer staging and poor general
conditions.
In these 69 patients in our study, local progresses
occurred in 15 cases (21.74%), which showed that local pro-
gresses of pulmonary malignancies after PMCT treatment
was still a mean problem for PMCT. In further study, it
was found that a possible reason might be relevant to the
tumor size; the larger the tumor was, the higher the recur-
rent rate was. Wolf et al. [24] reported that for patients with
tumor diameter >3 cm, 26% of them had a residual tumor
at MWA parts, 22% of them had recurrent tumor. In our
group, among 69 cases of ablated masses, all the five cases
whose masses were >4 cm in diameter before treatment
had local progress after the PMCT, and patients with mass
greater than 4 cm in diameter had a significantly higher
ratio of local progress compared with masses of other sizes,
which suggested that when the tumor mass was >4 cm in
diameter it seemed to be a risk factor for the local tumorprogress and might be exclusion criteria for microwave
treatment.
Conclusion
Ablating pulmonary malignancies with microwave was a
safe and effective method, which could obviously be
beneficial for the improvement of pulmonary malignancies
treatment effect although further observation was still
needed for its long-term effect.
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